CLINICAL_TRIALS
trial_result
· 2012-05-14
Clinical Trial Update: Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization) [Phase 1]
Summary
A Phase 1 clinical trial update on HKI-272 (neratinib) assessing its effect on cardiac repolarization in breast cancer patients has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Puma Biotechnology, Inc. | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED